Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Biovaxys Technology Corp (BVAXF)

Biovaxys Technology Corp (BVAXF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade BVAXF with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0661 +43.27%
on 05/11/22
0.1320 -28.26%
on 04/20/22
-0.0202 (-17.58%)
since 04/19/22
3-Month
0.0661 +43.27%
on 05/11/22
0.1400 -32.36%
on 03/01/22
-0.0395 (-29.43%)
since 02/18/22
52-Week
0.0661 +43.27%
on 05/11/22
0.5040 -81.21%
on 09/20/21
-0.0986 (-51.01%)
since 05/19/21

Most Recent Stories

More News
Advanced Clinical Trials Focus on Development of Vaccines to Prevent Ovarian Cancer Progression

Palm Beach, FL – May 18, 2022 – FinancialNewsMedia.com News Commentary – Companies in the Ovarian Cancer market are spending a lot of R&D on vaccine development, therapies and studies. For the past...

BIOV.CN : 0.130 (+4.00%)
BVAXF : 0.0947 (-1.66%)
CLSN : 2.34 (-5.26%)
IMGN : 3.53 (+0.71%)
ZNTL : 23.74 (-1.37%)
BMY : 75.96 (-1.38%)
BioVaxys Confirms First Clinical Site and Principal Investigators for Ovarian Cancer Vaccine Trial and Enters into Second Tumor Cell Supply Agreement

Vancouver, BC –  May 18, 2022 — BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV) (FRA: 5LB) (“BioVaxys” or “Company”), announced today that Hospices Civils de Lyon, France (“HCL”)...

BVAXF : 0.0947 (-1.66%)
BIOV.CN : 0.130 (+4.00%)
Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating

Palm Beach, FL – April 25, 2022 – FinancialNewsMedia.com News Commentary – The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer...

BIOV.CN : 0.130 (+4.00%)
BVAXF : 0.0947 (-1.66%)
CTIC : 4.87 (+9.93%)
IMGN : 3.53 (+0.71%)
CLVS : 0.7133 (-3.62%)
SBFM : 1.8200 (-3.70%)
Race to Develop Universal ‘Variant-Proof’ Covid Vaccine Involves Several Players

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – March 24, 2022 – USA News Group  –  Whenever a new COVID-19 variant emergences, health authorities have had limited options...

BIOV.CN : 0.130 (+4.00%)
BVAXF : 0.0947 (-1.66%)
SRNE : 1.5800 (+4.64%)
PFE : 50.65 (+0.50%)
BNTX : 167.87 (+6.88%)
MRNA : 143.38 (+4.12%)
Ineffectiveness Against Omicron Driving Development of Universal and Variant-Proof Vaccines

Biotech Insider – Despite early reports of a ‘ significant increase ’ in protection from mRNA against Omicron, calls for an Omicron-specific are ramping up, while there’s even more demand for a...

BIOV.CN : 0.130 (+4.00%)
BVAXF : 0.0947 (-1.66%)
GSK : 43.56 (-0.16%)
SNY : 53.06 (+1.28%)
NVAX : 58.43 (+12.13%)
AZN : 64.54 (+1.93%)
Demand for Greater Public Protection Calls for Creation of Next-Generation, Pan-COVID Vaccines

Biotech Insider – The US White House official briefing room recently released a statement dubbed “FACT SHEET: Consequences of Lack of Funding for Efforts to Combat COVID-19 if Congress Does Not Act”....

BIOV.CN : 0.130 (+4.00%)
BVAXF : 0.0947 (-1.66%)
AZN : 64.54 (+1.93%)
JNJ : 173.94 (-0.89%)
CVAC : 19.41 (+7.77%)
GSK : 43.56 (-0.16%)
Reducing the Risks of Adverse Reactions to Covid Vaccines May Also Reduce Hesitancy and Injuries

Biotech Insider – A new report from National Geographic has shone a light on topic only months ago was seen as too taboo to speak about on social media—serious vaccine side effects. As the US FDA continues...

BIOV.CN : 0.130 (+4.00%)
BVAXF : 0.0947 (-1.66%)
NVAX : 58.43 (+12.13%)
PFE : 50.65 (+0.50%)
BNTX : 167.87 (+6.88%)
MRNA : 143.38 (+4.12%)
Biotech Sector’s Response to Omicron Panic Should be Swift and Effective

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – December 7, 2021 – USA News Group  –  Despite a level of panic that JP Morgan has already downplayed in its 2022 forecasts,...

JPM : 118.31 (-1.48%)
BIOV.CN : 0.130 (+4.00%)
BVAXF : 0.0947 (-1.66%)
MRNA : 143.38 (+4.12%)
BNTX : 167.87 (+6.88%)
PFE : 50.65 (+0.50%)
NVAX : 58.43 (+12.13%)
Anxious World Waits As Covid Vaccine Makers Address Omicron Variant

Palm Beach, FL – December 7, 2021 – FinancialNewsMedia.com News Commentary There are many unknowns surrounding the new omicron Covid variant; there are early signs it’s more transmissible, but it’s...

BIOV.CN : 0.130 (+4.00%)
BVAXF : 0.0947 (-1.66%)
GSK : 43.56 (-0.16%)
JNJ : 173.94 (-0.89%)
SRNE : 1.5800 (+4.64%)
RDHL : 1.0500 (-1.87%)
BIOVAXYS ANNOUNCES MAJOR RESEARCH COLLABORATION WITH THE OHIO STATE UNIVERSITY TO DEVELOP BROADLY REACTIVE PAN-SARBECOVIRUS VACCINE

VANCOUVER, BC – December 7, 2021 – BioVaxys Technology Corp. (OTCQB: BVAXF) (CSE: BIOV.CNQ) (OTCQB:BVAXF) (“BioVaxys” or “Company”), a clinical-stage immunotherapy company developing novel...

BIOV.CN : 0.130 (+4.00%)
BVAXF : 0.0947 (-1.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.1052
2nd Resistance Point 0.1031
1st Resistance Point 0.0989
Last Price 0.0947
1st Support Level 0.0926
2nd Support Level 0.0905
3rd Support Level 0.0863

See More

52-Week High 0.5040
Fibonacci 61.8% 0.3367
Fibonacci 50% 0.2851
Fibonacci 38.2% 0.2334
Last Price 0.0947
52-Week Low 0.0661

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar